Publications by authors named "Lisa Blixt"

Claim this Profile
O
Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: focus on the very early period and Omicron era.
Pontus Hedberg, Lisa Blixt, Sandra Eketorp Sylvan, Isabela Killander Möller, Hannes Lindahl

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of COVID-19 hospitalisation by HIV-status and SARS-CoV-2 vaccination status during pre- and post-Omicron era in a national register-based cohort study in Sweden.
Isabela Killander Möller, Pontus Hedberg, Philippe Wagner, Hannes Lindahl, Sofia Nyström, Lisa Blixt

Infect Dis (Lond)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inborn errors of immunity are associated with increased COVID-19-related hospitalization and intensive care compared to the general population.
Hannes Lindahl, Fredrik Kahn, Åsa Nilsdotter-Augustinsson, Mats Fredrikson, Pontus Hedberg, Lisa Blixt

J Allergy Clin Immunol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uptake of the first to fifth doses of coronavirus disease 2019 vaccine in individuals with chronic lymphocytic leukaemia: A nationwide cohort study in Sweden.
Pontus Hedberg, Lisa Blixt, Fredrik Granath, Peter Bergman, Christina Carlander

EJHaem· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia.
Hanna M Ingelman-Sundberg, Lisa Blixt, David Wullimann, Jinghua Wu, Yu Gao

Haematologica· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination.
Lisa Blixt, Yu Gao, David Wullimann, Hanna Murén Ingelman-Sundberg, Sandra Muschiol

Blood· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial.
Lisa Blixt, David Wullimann, Soo Aleman, Jeanette Lundin, Puran Chen

Haematologica· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.
Lisa Blixt, Gordana Bogdanovic, Marcus Buggert, Yu Gao, Sophia Hober

Leukemia· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
Peter Bergman, Ola Blennow, Lotta Hansson, Stephan Mielke, Piotr Nowak, Lisa Blixt

EBioMedicine· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis